➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Moodys
Baxter
McKinsey
Colorcon

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,493,470


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,493,470 protect, and when does it expire?

Patent 9,493,470 protects ICLUSIG and is included in one NDA.

This patent has seventeen patent family members in nine countries.

Summary for Patent: 9,493,470
Title:Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyljbenzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methyl piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein. The instant application is directed to novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl}phenyl}benzamide and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin- -1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, compositions comprising such crystalline forms, and to methods of their preparation and use.
Inventor(s): Murray; Christopher K. (Lexington, MA), Rozamus; Leonard W. (Andover, MA), Chaber; John J. (Westford, MA), Sharma; Pradeep (Westford, MA)
Assignee: ARIAD PHARMACEUTICALS, INC. (Cambridge, MA)
Application Number:14/651,577
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 9,493,470

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-004 Dec 18, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-003 Apr 23, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ⤷  Try it Free
Takeda Pharms Usa ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-003 Apr 23, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y Y A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,493,470

PCT Information
PCT FiledDecember 12, 2013PCT Application Number:PCT/US2013/074571
PCT Publication Date:June 19, 2014PCT Publication Number: WO2014/093579

International Family Members for US Patent 9,493,470

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013204506 ⤷  Try it Free
Australia 2016210725 ⤷  Try it Free
Australia 2018201013 ⤷  Try it Free
Australia 2019240721 ⤷  Try it Free
Canada 2815506 ⤷  Try it Free
Canada 3022250 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Express Scripts
Medtronic
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.